Alexandria Real Estate Equities (ARE) Research

Forward Estimates

EPS Estimates

Current Qtr

$0.12

$0.12$0.12

vs $0.48-75.0%

1 analyst

Next Qtr

$-0.05

$-0.05$-0.05

vs $0.50-110.0%

1 analyst

Current Yr

$1.85

$0.81$2.34

vs $-8.44+121.9%

5 analysts

Next Yr

$-0.88

$-0.88$-0.88

1 analyst

Revenue Estimates

Current Qtr

$656.31M

$652.35M$658.64M

vs $762.04M-13.9%

4 analysts

Next Qtr

$644.97M

$619.10M$663.63M

vs $751.94M-14.2%

4 analysts

Current Yr

$2.65B

$2.54B$2.86B

vs $3.03B-12.4%

6 analysts

Next Yr

$2.68B

$2.48B$2.86B

vs $2.65B+1.0%

6 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for ARE on EDGAR.

ARE filing events and research context
Filed	Item	Context
Jan 26, 2026	business	Alexandria Real Estate Equities, Inc. (ARE) is a specialized life science REIT that develops and operates "Megacampus" ecosystems within premier innovation clusters, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. As of December 31, 2025, the company maintains a market capitalization of $20.75 billion with a North American portfolio comprising 35.9 million rentable square feet (RSF) of operating properties and 3.5 million RSF of Class A/A+ properties under construction. The tenant base is diversified across multinational pharmaceutical companies, biotechnology firms, academic research institutions, and government agencies, with investment-grade or publicly traded large-cap tenants accounting for 53% of total annual rental revenue. Current operating occupancy stands at 90.9%, compared to a 10-year average of 95%. Beyond real estate, ARE leverages a venture capital platform to provide strategic capital to transformative life science companies. This integrated model aims to drive higher occupancy, longer lease terms, and increased asset value by concentrating high-growth scientific and technological tenants in collaborative, high-density environments.
Jan 26, 2026	mda	Alexandria Real Estate Equities (ARE) operates a portfolio of Class A/A+ life science "Megacampus" ecosystems across AAA clusters, including Greater Boston, the San Francisco Bay Area, and San Diego. As of December 31, 2025, the company manages 35.9 million RSF of operating properties with 90.9% occupancy and 3.5 million RSF under construction. The financial strategy relies on triple net leases, which cover 92% of annual rental revenue, to mitigate inflationary operating costs. However, ARE faces significant structural headwinds, including a contraction in life science venture capital and a shift toward de-risked, later-stage assets. Regulatory risks are acute, highlighted by proposed 40% cuts to the NIH budget for FY2026, FDA workforce reductions, and "Most-Favored-Nation" drug pricing mandates. Macroeconomic pressures include aggressive tariffs on Chinese and North American imports, which threaten to increase construction costs and disrupt tenant supply chains. Additionally, the rapid expansion of China’s biotechnology sector poses a long-term threat to U.S. R&D demand. Reflecting these challenges, the Board reduced the quarterly cash dividend by 45% in December 2025.
Jan 26, 2026	risk_factors	Alexandria Real Estate Equities faces significant financial risks centered on asset valuation and market volatility within its AAA life science innovation clusters. A primary concern is the impairment of long-lived assets; the company recognized $2.2 billion in real estate impairments in 2025, reflecting high subjectivity in estimating future cash flows, rental rates, and exit capitalization rates. ARE is also exposed to tenant credit risk, requiring constant monitoring of life science tenants' financial health to prevent lease defaults. Market risks include interest rate volatility affecting the fair value of consolidated debt and earnings from variable-rate debt. Additionally, the company holds equity investments in public and private life science entities, exposing it to equity price fluctuations. Operational risks extend to foreign currency exchange volatility related to its Canadian portfolio. Inflation also poses a direct and indirect threat to business operations. The company's heavy reliance on Megacampus ecosystems in specific markets, including Greater Boston, the San Francisco Bay Area, and San Diego, concentrates its exposure to regional economic shifts and the specific demands of the life science industry.

Filed

Item

Context

Jan 26, 2026

business

Alexandria Real Estate Equities, Inc. (ARE) is a specialized life science REIT that develops and operates "Megacampus" ecosystems within premier innovation clusters, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. As of December 31, 2025, the company maintains a market capitalization of $20.75 billion with a North American portfolio comprising 35.9 million rentable square feet (RSF) of operating properties and 3.5 million RSF of Class A/A+ properties under construction. The tenant base is diversified across multinational pharmaceutical companies, biotechnology firms, academic research institutions, and government agencies, with investment-grade or publicly traded large-cap tenants accounting for 53% of total annual rental revenue. Current operating occupancy stands at 90.9%, compared to a 10-year average of 95%. Beyond real estate, ARE leverages a venture capital platform to provide strategic capital to transformative life science companies. This integrated model aims to drive higher occupancy, longer lease terms, and increased asset value by concentrating high-growth scientific and technological tenants in collaborative, high-density environments.

Jan 26, 2026

mda

Alexandria Real Estate Equities (ARE) operates a portfolio of Class A/A+ life science "Megacampus" ecosystems across AAA clusters, including Greater Boston, the San Francisco Bay Area, and San Diego. As of December 31, 2025, the company manages 35.9 million RSF of operating properties with 90.9% occupancy and 3.5 million RSF under construction. The financial strategy relies on triple net leases, which cover 92% of annual rental revenue, to mitigate inflationary operating costs. However, ARE faces significant structural headwinds, including a contraction in life science venture capital and a shift toward de-risked, later-stage assets. Regulatory risks are acute, highlighted by proposed 40% cuts to the NIH budget for FY2026, FDA workforce reductions, and "Most-Favored-Nation" drug pricing mandates. Macroeconomic pressures include aggressive tariffs on Chinese and North American imports, which threaten to increase construction costs and disrupt tenant supply chains. Additionally, the rapid expansion of China’s biotechnology sector poses a long-term threat to U.S. R&D demand. Reflecting these challenges, the Board reduced the quarterly cash dividend by 45% in December 2025.

Jan 26, 2026

risk_factors

Alexandria Real Estate Equities faces significant financial risks centered on asset valuation and market volatility within its AAA life science innovation clusters. A primary concern is the impairment of long-lived assets; the company recognized $2.2 billion in real estate impairments in 2025, reflecting high subjectivity in estimating future cash flows, rental rates, and exit capitalization rates. ARE is also exposed to tenant credit risk, requiring constant monitoring of life science tenants' financial health to prevent lease defaults. Market risks include interest rate volatility affecting the fair value of consolidated debt and earnings from variable-rate debt. Additionally, the company holds equity investments in public and private life science entities, exposing it to equity price fluctuations. Operational risks extend to foreign currency exchange volatility related to its Canadian portfolio. Inflation also poses a direct and indirect threat to business operations. The company's heavy reliance on Megacampus ecosystems in specific markets, including Greater Boston, the San Francisco Bay Area, and San Diego, concentrates its exposure to regional economic shifts and the specific demands of the life science industry.

Forward Estimates

ARE filing events and research context

Keep researching ARE

Related tickers

Related explainers

Forward Estimates